Taxifolin Glycoside Blocks Human ether-a-go-go Related Gene K⁺ Channels

Jihyun Yun¹, Hyemi Bae¹, Sun Eun Choi¹, Jung-Ha Kim¹, Young Wook Choi⁶, Inja Lim¹, Chung Soo Lee², Min Won Lee⁶, Jae-Hong Ko¹, Seong Jun Seo³, and Hyoweon Bang¹

Departments of ¹Physiology, ²Pharmacology, ³Dermatology, ⁴Family Medicine, College of Medicine, Chung-Ang University, Seoul 156-756, ⁵Department of Cosmetology Science, Nambu University, Gwangju 506-706, ⁶College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea

Taxifolin glycoside is a new drug candidate for the treatment of atopic dermatitis (AD). Many drugs cause side effects such as long QT syndrome by blocking the human ether-a-go-go related gene (hERG) K⁺ channels. To determine whether taxifolin glycoside would block hERG K⁺ channels, we recorded hERG K⁺ currents using a whole-cell patch clamp technique. We found that taxifolin glycoside directly blocked hERG K⁺ current in a concentration-dependent manner (EC₅₀=9.6±0.7 μM). The activation curve of hERG K⁺ channels was negatively shifted by taxifolin glycoside. In addition, taxifolin glycoside accelerated the activation time constant and reduced the onset of the inactivation time constant. These results suggest that taxifolin glycoside blocks hERG K⁺ channels that function by facilitating activation and inactivation process.

Key Words: hERG K⁺ channel, Long QT syndrome, Patch clamp, Taxifolin glycoside

INTRODUCTION

Atopic dermatitis (AD) is an inflammatory, chronically relapsing, non-contagious and pruritic skin disorder characterized by allergic symptoms such as redness, inflammation, and itching [1]. More studies of anti-atopic agents must be conducted because the exact pathogenesis of AD is unknown and a definitive treatment is lacking.

Taxifolin 3-O- β-D-glucopyranoside (taxifolin glycoside) is a flavonoid compound isolated from Rhododendron mucronulatum, which has been used for treatment of rheumatitis, neuralgia, and inflammation traditional oriental medicine [2,3]. Recent studies indicate that taxifolin glycoside inhibits dendritic cell-mediated immune response and demonstrates anti-inflammatory activity in NC/Nga mice: an atopic dermatitis model [4,5]. In a therapeutic efficacy study in NC/Nga mice with AD-like lesions, a rapid and profound restoration of skin barrier function was observed in the group treated with the taxifolin glycoside-loaded Pep-1 peptide-conjugated elastic liposomes (Pep1-EL) formulation [6]. So far, taxifolin glycoside has been tested as a potential therapeutic for AD.

The K⁺ channel controlled by the human ether-a-go-go related gene (hERG) conducts the rapidly activating delayed rectifier K⁺ current (Iₖr) in cardiac myocytes, which plays a central role in the repolarization of action potentials [1-3]. Loss of function or blockade of the hERG K⁺ channel can induce long QT syndrome (LQTS), which is characterized by a prolonged QT interval on an electrocardiogram and can result in fatal arrhythmias such as torsade de points [7,8]. Many drugs have reported side effects, including hERG K⁺ current inhibition, which can lead to acquired LQTS [9-12]. However, little information is available regarding the anti-arrhythmic effect and hERG K⁺ channel blockade that are caused by taxifolin glycoside. In this study, we tested the cardiovascular safety of taxifolin glycoside by examining its effects on hERG K⁺ channels using a whole cell patch clamp method.

METHODS

Cell cultures

hERG cDNA was a generous gift from Dr. Tong Mook Kang, Ph.D. (Professor, Department of Physiology, College of Medicine, Sungkyunkwan University, Suwon, Korea). hERG cDNA was subcloned into mammalian expression vector pcDNA3.1 (Invitrogen) for transfection into cells. Transfection of hERG into Chinese Hamster Ovary (CHO)
cells was achieved via the lipofectamin method (Life Technologies). The stably transfected hERG-CHO cells were generated through G418 (Gibco) antibiotic selection. The transfected clones were selected through the use of 1,000 μg/ml of G418. The CHO cells stably expressed hERG (hERG-CHO) were maintained in F-12 supplemented with 10% (v/v) fetal bovine serum (FBS) and 500 μg/ml G418. For electrophysiological recordings, the cells were harvested from the culture dish via trypsinization and were seeded onto a glass coverslip.

**Taxifolin glycoside**

Taxifolin glycoside was kindly provided from Dr. Min Won Lee, Ph.D. (Professor, College of Pharmacy, Chung-Ang University, Seoul, Korea) and was dissolved in distilled water to obtain a 500 mM stock solution, which was stored at −20°C. Taxifolin glycoside was diluted in external solution to achieve the final concentration.

**Electrophysiological recordings**

The hERG K⁺ currents were recorded using the whole-cell patch clamp technique. Cells on a coverslip were transferred to a recording chamber mounted on the stage of an inverted microscope (Olympus). For the hERG K⁺ current recording, the bath was perfused with HEPES-buffered Tyrode solution containing (in mM) NaCl 155, KCl 5, MgCl₂ 1, HEPES 10, and glucose 10 (pH 7.3 with NaOH). The bath solution was perfused at a rate of 0.7 ml/min. The pipette solution contained (in mM) KCl 140, Mg-ATP 5, MgCl₂ 1, KH₂PO₄ 10, EGTA 0.1, and HEPES 5 (pH 7.2 with KOH). The electrodes were constructed from borosilicate glass (WPI) using a micropipette puller (Narishige) and were heat-polished with a microforge (Narishige). The resistance of the electrode when filled with the pipette solution was 2~3 MΩ. Membrane currents were recorded with an Axopatch 200B amplifier (Axon Instruments) and a Digidata 1322A (Axon Instruments). Currents were filtered at 2 kHz and digitized at 10 kHz. Capacitance and series resistance compensations were optimized. The pCLAMP 9.2 software (Axon Instruments) was used to generate voltage clamp protocols, acquire data, and analyze current traces.

**Statistical analysis**

Data were expressed as mean±standard error of the mean (SEM). Data analysis and curve fitting were performed with Clampfit 9.2 (Axon Instruments) and Origin 8.0 software (OriginLab). Statistical comparisons were made using a paired t-test. p-values < 0.05 were considered statistically significant.

**RESULTS**

We investigated the effect of taxifolin glycoside on hERG K⁺ current stably expressed in CHO cells using the whole-cell patch clamp technique. The hERG K⁺ currents were
elicit a holding potential of +80 mV by the test pulses ranging from −60 mV to +40 mV in 10 mV steps (I_{t,r}) for each test pulse. This was followed by a repolarization step to −50 mV for 2 seconds to evoke tail current (I_{t,r}).

The hERG K⁺ currents were first recorded under control conditions, and then 30 μM taxifolin glycoside was added into the bath for 20 minutes. Taxifolin glycoside reduced tail currents of hERG K⁺ channels during the depolarization phase of the test pulse (Fig. 1A). Normalized current-voltage (I-V) relationships of I_{t,r} are illustrated in Fig. 1B (n=5), which shows that I_{t,r} was increased with depolarizing voltages and reached a plateau at approximately +30 mV. Taxifolin glycoside reduced I_{t,r} amplitudes after a test pulse to 0 mV.

At taxifolin glycoside concentrations of 5, 10, 30, 50 and 100 μM, the peak amplitude of the I_{t,r} were measured in the same cell and were normalized to the control value. Taxifolin glycoside blocked I_{t,r} in a concentration-depend-ent manner. To obtain the half-maximal effective concentration (EC_{50}) of taxifolin glycoside, the concentration-response relationships of I_{t,r} were fitted using the Hill equation. The EC_{50} of taxifolin glycoside was 9.6±0.7 μM (n=5, Fig. 1C). The fractional blockages in I_{t,r} were 12.0±2.5%, 18.1±4.7%, 26.3±4.5%, 35.4±5.6% and 36.9±3.0% in the 5, 10, 30, 50 and 100 μM taxifolin glycoside groups, respectively (n=5). The effect of taxifolin glycoside was irreversible (data not shown).

To further understand the inhibitory effect of taxifolin glycoside on hERG K⁺ channels, we investigated the changes in channel kinetics induced by taxifolin glycoside.

We first examined the effects of 30 μM taxifolin glycoside on the time constants of activation and the activation curve. To obtain the time constant of activation, the increasing phase of I_{t,r} in Fig. 1A was fitted to a single exponential function for test potentials in the range of -30 mV to +20 mV. The time constant of activation was significantly smaller in the presence of 30 μM taxifolin glycoside and their time constants were reduced by 29.9±4.3% at +10 mV (n=5, p<0.05, Fig. 2A). Relative to the control, hERG K⁺ currents after taxifolin glycoside treatment activated more rapidly. The activation curve was constructed by normalizing the I_{t,r} shown in Fig. 1A. The normalized data were plotted against the voltage and fitted with the Boltzmann function (Fig. 2B). Taxifolin glycoside significantly changed the half-maximal activation voltages (V_{1/2}; 2.7±2.1 mV and −2.2±0.1 mV; in the control group and in the group treated with 30 μM taxifolin glycoside, respectively; n=5, p<0.05). A 30 μM concentration of taxifolin glycoside produced a significant negative shift of the activation curve.

We next examined the effects of taxifolin glycoside on the steady-state inactivation, onset of inactivation and recovery from inactivation. To measure steady-state inactivation, a special protocol was used to inactivate the channel at a holding potential of +20 mV for 2 seconds, recover the channel from inactivation at various potentials ranging from −120 mV to +60 mV for 15 seconds in 10 mV steps, and then measure the resulting peak outward current at a constant +20 mV in the absence and the presence of 30 μM taxifolin glycoside (Fig. 3A). In Fig. 3B, the inactivation outward current amplitude was normalized and plotted against the test pulse potential, producing the steady-state inactivation curve. This curve was fitted with a Boltzmann function. Taxifolin glycoside did not affect the half-maximal inactivation values of hERG K⁺ channels (V_{1/2}; −43.3±5.4 mV and −37.8±7.4 mV; in control and after treatment with 30 μM taxifolin glycoside, respectively; n=5). The time constant of channel inactivation was also assessed. To obtain the time constants of steady-state inactivation, the decays of the outward current in Fig. 3A were fitted to single exponential functions and plotted against voltages (Fig. 3C). Although taxifolin glycoside caused a slight decrease in the time constants of direct channel inactivation, the changes were not statistically significant (n=5, p>0.05).

A 3-pulse protocol was used to assess the onset rate of channel inactivation. The channels were first inactivated by clamping the membrane at +20 mV for 2 seconds, followed by a prepulse to −120 mV for 15 microseconds. This prepulse was sufficient to allow for the rapid recovery of channels from inactivation, but short enough to prevent significant channel deactivation. Following the recovery prepulse, a series of test pulses were delivered with po-
Fig. 3. Effects of taxifolin glycoside on the steady-state inactivation of the hERG K⁺ channels. (A) Representative current traces for the steady-state inactivation in control and 30 μM taxifolin glycoside treated sample. (B) Normalized steady-state inactivation curves before and after exposure to 30 μM taxifolin glycoside. Smooth curves were fitted with the Boltzmann function (n=5). (C) The time constants of steady-state inactivation. The time constants obtained from a single exponential fit the decay of the outward current (n=5).

Fig. 4. Effects of taxifolin glycoside on the onset of inactivation of hERG K⁺ channels. (A) Representative current traces for the onset of inactivation in control and 30 μM taxifolin glycoside treated sample. (B) The time constant for the onset of inactivation were measured by fitting a single exponential function to the decaying current (n=5, *p < 0.05).
Effect of Taxifolin Glycoside on hERG K⁺ Channels

Effect of Taxifolin Glycoside on hERG K⁺ Channels

41

Fig. 5. Effect of taxifolin glycoside on the recovery from inactivation of hERG K⁺ channels. (A) Representative current traces for the recovery from inactivation in control and 30 μM taxifolin glycoside-treated sample. (B) The time constant for the recovery from inactivation were obtained by fitting a single exponential function to the initial increase in tail current amplitude (n=5).

DISCUSSION

The present study demonstrated that taxifolin glycoside directly blocks hERG K⁺ channels in hERG-CHO cells. Taxifolin glycoside induced 2 distinct changes in hERG K⁺ channel gating: (1) facilitating activation (negative shift of the voltage-dependence of activation and accelerated activation time constant) and (2) facilitating of inactivation (reduced onset of inactivation time constant).

In Fig. 1, the blockage by taxifolin glycoside was significantly increased at +30 mV at which point the hERG K⁺ channel was fully activated. These results suggest that blockage by taxifolin glycoside might occur via open-state blockade. In addition, the hERG K⁺ channel kinetics related to activation were changed. Taxifolin glycoside produced a significant negative shift of the activation curve, and the time constant of activation was significantly decreased in the presence of taxifolin glycoside (n=5, p<0.05, Fig. 4B).

The fully activated I-V protocol was used to determine the recovery from inactivation. Each current was obtained through depolarization to +20 mV for 2 seconds to inactivate the hERG K⁺ channels, followed by varying the repolarizing pulses to test potentials between -120 mV and +30 mV in 10 mV steps. The prepulse potential at +20 mV was sufficiently positive to induce full conductance of the hERG K⁺ channels but also rendered a large number of the channels inactive. The current traces for recovery from inactivation in the absence and the presence of 30 μM taxifolin glycoside are shown in Fig. 5A. The increasing phase of the tail current represents the rapid recovery from inactivated states to open states. The time constant for recovery from inactivation were obtained by fitting a single exponential function to the initial increase in tail current amplitude (n=5, Fig. 5B). Taxifolin glycoside did not affect the time constants for recovery from inactivation.

The fully activated I-V protocol was used to determine the recovery from inactivation. Each current was obtained through depolarization to +20 mV for 2 seconds to inactivate the hERG K⁺ channels, followed by varying the repolarizing pulses to test potentials between -80 mV and +60 mV, resulting in large, outward inactivating currents. The current traces at the onset of inactivation in the absence and the presence of 30 μM taxifolin glycoside are shown in Fig. 4A. The time constants for the onset of inactivation were obtained by fitting a single exponential function to the decaying current traces during the third pulse of the protocol. The time constants of onset of inactivation were significantly decreased in the presence of 30 μM taxifolin glycoside (n=5, p<0.05, Fig. 4B).

The fully activated I-V protocol was used to determine the recovery from inactivation. Each current was obtained through depolarization to +20 mV for 2 seconds to inactivate the hERG K⁺ channels, followed by varying the repolarizing pulses to test potentials between -120 mV and +30 mV in 10 mV steps. The prepulse potential at +20 mV was sufficiently positive to induce full conductance of the hERG K⁺ channels but also rendered a large number of the channels inactive. The current traces for recovery from inactivation in the absence and the presence of 30 μM taxifolin glycoside are shown in Fig. 5A. The increasing phase of the tail current represents the rapid recovery from inactivated states to open states. The time constant for recovery from inactivation were obtained by fitting a single exponential function to the initial increase in tail current amplitude (n=5, Fig. 5B). Taxifolin glycoside did not affect the time constants for recovery from inactivation.
The maximum inhibitory effects on hERG K+ currents was has the possibility to induce a cardiac arrhythmia, although therapeutic plasma concentrations. Taxifolin glycoside also that are effective IC50 which define the half concentration between the top and bottom plateaus of the curve [16]. Based on this data, the maximum therapeutic plasma concentration of taxifolin glycoside should be \( \leq 0.32 \ \mu M \). Recently, taxifolin glycoside has demonstrated anti-inflammatory and immune modulatory effects at concentrations between 10 and 20 \( \mu M \) in \textit{in vitro} experiments [4-6]. However, the concentrations that are effective \textit{in vitro} are higher than the recommended therapeutic plasma concentrations. Taxifolin glycoside also has the possibility to induce a cardiac arrhythmia, although the maximum inhibitory effects on hERG K+ currents was 36.9±3.0%, and taxifolin glycoside concentrations \( \geq 100 \ \mu M \) did not produce a further decrease of hERG K+ currents. Since outward K+ currents play an important role during plateau repolarization and in determining the configuration of the action potential, small changes in conductance can significantly alter the effective refractory period, hence the action potential duration [17]. So, if we use taxifolin glycoside as a topical ointment to treat inflammatory skin lesions such as atopic dermatitis and contact dermatitis, such treatment would be unlikely to produce side effects because the transcutaneous absorption rate is \( \leq 1\% \) that of oral delivery or injection.

In conclusion, taxifolin glycoside inhibited hERG K+ currents that function by facilitating activation and inactivation process. Our results provide an understanding of the cardiovascular risk profile of the new drug taxifolin glycoside.

**ACKNOWLEDGEMENTS**

This study was supported by a Grant from the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea (A091121).

**REFERENCES**

1. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160.
2. Takahashi H, Hirata S, Minami H, Fukuyama Y. Triterpene and flavanone glycoside from Rhododendron simaizi. Phytoche-

mistry. 2001;56:875-879.
3. Kim CM, Shin MK, Ahn DK, Lee KS. An unabridged dictionary of Chinese herbs. Jeongdam Publication; 1998. 1464-1472 p.
4. Kim YJ, Choi SE, Lee MW, Lee CS. Taxifolin glycoside inhibits dendritic cell responses stimulated by lipopolysaccharide and lipoteichoic acid. J Pharm Pharmacol. 2008;60:1465-1472.
5. Ahn JY, Choi SE, Jeong MS, Park KH, Moon NJ, Joo SS, Lee CS, Choi YW, Li K, Lee MK, Lee MW, Seo SJ. Effect of taxifolin glycoside on atopic dermatitis-like skin lesions in NC/Nga mice. Phytother Res. 2010;24:1071-1076.
6. Kang MJ, Euns JY, Park SH, Kang MH, Park KH, Choi SE, Lee MW, Kang KH, Oh CH, Choi YW. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm. 2010;402:198-204.
7. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625-1633.
8. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760-781.
9. Caverio I, Mestre M, Guillén JM, Crouch W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother. 2000;1:947-973.
10. Delisle BP, Anson BD, Rajamani S, January CT. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 2004;94:1418-1428.
11. Lee SH, Hahn SJ, Min G, Kim J, Jo SH, Choe H, Choi BH. Inhibitory actions of hERG currents by the immunosuppressant drug cyclosporin a. Korean J Physiol Pharmacol. 2011;15:291-297.
12. Lee HA, Kim KS, Hyun SA, Park SG, Kim SJ. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels. Korean J Physiol Pharmacol. 2012;16:327-332.
13. Zhao XL, Qi ZP, Fang C, Cao MH, Ly YJ, Li BX, Yang BF. hERG K+ channel blockade by the novel antiviral drug sophocarpine. Biol Pharm Bull. 2008;31:627-632.
14. Towart R, Linders JT, Hermans AN, Rohrlacher J, van der Linde HJ, Ercken M, Cik M, Roovers P, Teismann A, Gallacher DJ. Blockade of the \( \mathrm{I}_{\text{Kr}} \) potassium channel: an overlooked cardiovascular liability in drug safety screening? J Pharmaco-logical Methods. 2009;60:1-10.
15. Redfern WS, Carlsson L, Davis AS, Lynch WM, MacKenzie I, Palathorpe S, Siegl PK, Strang I, Sullivan AT, Wallace R, Cann A, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
16. Neubig RR, Spekling M, Kenakin T, Christopoulos A. International union of pharmacology committee on receptor nomenclature and drug classification. International union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2005;55:597-606.
17. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev. 2005;25:133-166.